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Abstract
Background Budesonide foam, a rectally administered,
second-generation corticosteroid with extensive hepatic
first-pass metabolism, is efficacious for the treatment of
mild-to-moderate ulcerative proctitis and ulcerative
proctosigmoiditis.
Aim The aim of this study was to comprehensively assess
the safety and pharmacokinetic profile of budesonide foam.
Methods Data from five phase III studies were pooled to
further evaluate safety, including an open-label study
(once-daily treatment for 8 weeks), an active-comparator
study (once-daily treatment for 4 weeks), and two placebo-
controlled studies and an open-label extension study
(twice-daily treatment for 2 weeks, then once daily for
4 weeks). Data from the placebo-controlled studies and
two phase I studies (i.e., patients with mild-to-moderate
ulcerative colitis and healthy volunteers) were pooled to
evaluate the pharmacokinetics of budesonide foam.
Results A similar percentage of patients reported adverse
events in the budesonide foam and placebo groups, with the
majority of adverse events beingmild ormoderate in intensity
(93.3 vs 96.0 %, respectively). Adverse events occurred in
41.4 and 36.3 % of patients receiving budesonide foam and
placebo, respectively. Mean morning cortisol concentrations
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remained within the normal range for up to 8 weeks of
treatment; there were no clinically relevant effects of
budesonide foam on the hypothalamic–pituitary–adrenal
axis. Population pharmacokinetic analysis demonstrated low
systemic exposure after budesonide foam administration.
Conclusions This integrated analysis demonstrated that
budesonide foam for the induction of remission of distal
ulcerative colitis is safe overall, with no clinically relevant
effects on the hypothalamic–pituitary–adrenal axis.
Keywords Ulcerative colitis  Ulcerative proctitis 
Ulcerative proctosigmoiditis  Budesonide foam  Safety 
Pharmacokinetics
Introduction
Ulcerative colitis (UC), a chronic inflammatory bowel
disease, is stratified by the extent of colonic involvement:
ulcerative proctitis (UP), ulcerative proctosigmoiditis
(UPS), left-sided, extensive, and pancolitis [1–3]. In UP,
inflammation is limited to the rectum (i.e., distal to the
rectosigmoid junction), while inflammation in UPS, con-
sidered a form of distal UC, is characterized by rectal and
sigmoid inflammation without involvement of the
descending colon [2–4]. Approximately 46 % of patients
with UC have UP or UPS [4, 5]. Clinical symptoms of UC
include rectal bleeding, diarrhea, urgency, tenesmus, and
abdominal pain [1], with some patients with limited distal
UC also experiencing paradoxical constipation [6].
First-line therapy for induction of remission is rectal
5-aminosalicylate (5-ASA) formulations (i.e., suppository,
foam, or enema) for patients with UP, and rectal 5-ASA
alone or in combination with oral 5-ASA for patients with
more proximal left-sided disease involvement [7–10].
5-ASA preparations are slow to act, and for patients with
more significant symptoms, rectally administered corti-
costeroids are considered second-line therapy for induction
of more rapid remission in patients with UP or UPS.
However, conventional corticosteroids are associated with
undesirable systemic effects, which limit their use.
Rectal therapies include suppositories, enemas, or foam
preparations. Suppositories are not only difficult for some
patients to administer [11], but the use of suppositories is
restricted by their limited proximal distribution within the
rectum [12], in contrast to foam preparations, which can
spread to the descending colon [13]. Foam preparations pro-
videgreater retentionandmore uniformdistributionwithin the
distal colon and rectum compared with enema preparations
[14–16]. In addition, rectal foam preparations are generally
preferred by patients over rectal enema formulations [17].
Budesonide foam, a rectally administered second-genera-
tion corticosteroid, has minimal systemic effects due to
extensive first-pass metabolism in the liver after absorption.
Budesonide foam was efficacious for the treatment of active
UP andUPS in four phase III studies, including a randomized,
active-controlled, multicenter study [18], and a randomized,
double-blind, double-dummy, multicenter study [17]. Also,
patients successfully completing two identically designed,
placebo-controlled, phase III trials [19] were permitted to
continue in a phase III, open-label extension study and receive
repeat cycles of budesonide foam for recurrent flares. In this
integrated analysis of safety, data from these five phase III
studies were pooled for a detailed evaluation of the safety of
budesonide foam. In addition, population pharmacokinetics
were assessed to characterize the systemic exposure parame-
ters of budesonide foambypoolingdata from the twoplacebo-
controlled trials [19] and two phase I trials [13].
Methods
Safety and Pharmacokinetic Populations
Safety Population
The safety population included patients from five studies: two
identically designed, placebo-controlled studies conducted in
the USA and Russia [BUCF3001 (Clinicaltrials.gov identifier
NCT01008410) and BUCF3002 (Clinicaltrials.gov identifier
NCT01008423)] [19], an active-comparator (i.e., hydrocor-
tisone foam) study conducted in Germany, Italy, and Israel
(BUF-6/UCA) [18], an active-comparator (i.e., budesonide
enema) study conducted in Germany, Hungary, Lithuania,
Latvia, Estonia, The Netherlands, and Israel (BUF-9/UCA)
[17], and an open-label extension study conducted in theUSA
for patients who completed BUCF3001 and BUCF3002 and
had recurrent flares of UP or UPS [BFPS3073 (Clinical
Trials.gov identifier NCT01349673)].
In the two phase III, identically designed, multicenter,
randomized, double-blind, placebo-controlled studies,
patients were randomized 1:1 to receive budesonide foam
2 mg/25 mL or placebo twice daily for 2 weeks, then once
daily for 4 weeks [19]. Each study consisted of a screening
phase, a run-in/stabilization phase of 4–7 days, a 6-week
treatment phase, and a 2-week follow-up phase. Patients
C18 years of age with active (endoscopy-confirmed) distal
UP or UPS, extending C5 cm, but no further than 40 cm
from the anal verge, and baseline Modified Mayo Disease
Activity Index (MMDAI) scores between 5 and 10, inclu-
sive, with subscale ratings C2 for endoscopic appearance
and rectal bleeding were eligible for enrollment. Concomi-
tant use of oral 5-ASA drugs at a stable dose up to 4.8 g/day
was permitted. Key exclusion criteria included use of sys-
temic, oral, topical, or rectal corticosteroids, or laxatives or
enemas (other than 5-ASAs) during the previous 14 days.
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In a phase III, multicenter, randomized, active-com-
parator (hydrocortisone foam), open-label study, patients
were randomized to receive budesonide foam 2 mg/20 mL
or hydrocortisone 100 mg/15 mL once daily for 8 weeks
[18]. Patients between 18 and 70 years of age with active
(endoscopy- and histology-confirmed) UP or UPS and a
disease activity index (DAI) C4 were eligible for enroll-
ment. Concomitant use of oral 5-ASA drugs at a stable
dose up to 2 g/day was permitted. Key exclusion criteria
included use of corticosteroids within 1 month or
immunomodulators within 3 months prior to baseline.
In a phase III, multicenter, randomized, double-blind,
double-dummy, active-comparator (budesonide enema)
study, patients were randomized to receive budesonide foam
2 mg/25 mL and placebo enema or budesonide enema 2 mg/
100 mL and placebo foam once daily for 4 weeks [17].
Patients between 18 and 70 years of age with active (en-
doscopy-, histology-, and negative stool culture-confirmed)
UP or UPS, a DAI[ 4, and an endoscopic index C4 were
eligible for enrollment. Concomitant use of 5-ASA drugs and
long-term nonsteroidal antiinflammatory drug treatment
were not permitted. Key exclusion criteria included use of
oral/rectal corticosteroids within 1 month or immunomodu-
lators within 3 months prior to baseline.
In a multicenter, open-label extension study (BFPS3073),
patients who completed BUCF3001 and BUCF3002 were
permitted to receive additional 6-week treatment cycles of
budesonide foam for recurrent flares of UP or UPS. When a
flare occurred, budesonide foam 2 mg was administered
rectally twice daily for 2 weeks followed by 2 mg once-
daily administration for 4 weeks.
Pharmacokinetics Population
The pharmacokinetics (PK) population included patients
from four studies: two identically designed, placebo-con-
trolled, phase III studies (BUCF3001 and BUCF3002) [19]
and two phase I studies [single-dose (BUF-4/BIO) [13],
and multiple-dose (BUF-7/BIO)]. In the single-dose, open-
label, single-center, phase I study conducted in Austria,
patients with active, mild-to-moderate UC, as defined by
the DAI [20], received a dose of 99mTc-labeled budesonide
foam 2 mg/20 mL [13]. In the multiple-dose, open-label,
single-center, phase I study conducted in Germany, healthy
male volunteers received a single dose of budesonide foam
2 mg on day 1, followed by budesonide foam 2 mg twice
daily from days 2 to 5.
Safety Assessments
Safety assessments included periodic monitoring of adverse
events (AEs), clinical laboratory tests [including morning
cortisol concentrations and adrenocorticotropic hormone
(ACTH) challenge tests], measurement of vital signs, and
monitoring of concomitant medications. For studies that
included an ACTH challenge test, patients were adminis-
tered a 250-lg dose of cosyntropin between 8 am and
10 am, or approximately within 2–4 h of waking, via
intramuscular injection. Blood for serum cortisol assess-
ments was drawn immediately prior to cosyntropin admin-
istration (baseline) and at a 30-min time point after the
challenge. Per protocol, adrenal insufficiency was defined as
having a serum cortisol concentration of B18 lg/dL at
30 min following ACTH challenge.
Pharmacokinetic Bioanalysis
Blood samples for pharmacokinetic assessments were
collected, and plasma budesonide concentrations were
determined using high-performance liquid chromatography
(HPLC)-dual mass spectroscopy. The effect of budesonide
foam on the hypothalamic–pituitary-adrenal (HPA) axis
was assessed by evaluating correlations of plasma budes-
onide maximum concentration (Cmax) and area under the
curve (AUC) values with results of the week-6 ACTH
challenge in studies BUCF3001 and BUCF3002.
Statistical Analyses
The safety population was defined as any enrolled patient
who received C1 dose of study medication. Demographic
and baseline disease characteristics, exposure, and safety
data were summarized using descriptive statistics. Two
models were used for the population pharmacokinetic
analysis: the traditional forward addition approach and the
single-objective hybrid genetic algorithm [SOHGA,
DARWINTM (Nuventra Pharma Sciences, Research Tri-
angle Park, NC)] [21, 22]. The traditional forward addition
approach, which used a p value\0.05 for a likelihood ratio
test (LRT), was used in combination with diagnostic fig-
ures and consideration of biologic plausibility to add fea-
tures to a trivial model (compartments, mixture models, lag
time, covariates). The SOHGA utilizes user-defined criteria
to provide a robust method for selecting population PK
models, designed to result in a large model (P\ 0.05),
convergence, a successful covariance step, and a successful
correlation and condition number test. The two models
were combined for a final forward addition/backward
elimination process, using the LRT with forward addition
and P\ 0.05 and backward elimination with P\ 0.01.
The final model used for analysis was a one-compartment
model with first-order absorption and an absorption lag
time.
3410 Dig Dis Sci (2015) 60:3408–3417
123
Results
Patients
The safety population for budesonide foam included 719
patients from five phase III trials, including two placebo-
controlled trials, two active-controlled trials, and one open-
label extension trial (Fig. 1). The safety population for
placebo included 278 patients from two phase III placebo-
controlled trials. The majority of patients in the placebo-
and active-controlled studies (84.3 % of patients in the
budesonide foam group and 86.3 % of patients in the pla-
cebo group) completed the studies.
Demographic and baseline characteristics were gener-
ally similar between groups (Table 1). A greater percent-
age of patients in the budesonide foam group had mild
disease severity compared with the placebo group (26.7 vs
12.2 %, respectively). In the overall budesonide foam
treatment group, fewer patients used 5-ASAs at baseline
compared with the placebo group (31.7 vs 55.4 %,
respectively); this is because concomitant use of 5-ASAs
was prohibited in one of the active-controlled studies.
However, when only studies that allowed the use of
5-ASAs at baseline were considered in the analysis, a
greater percentage of patients receiving budesonide foam
versus those receiving placebo also reported using 5-ASAs
at baseline (68.9 vs 55.4 %, respectively). The mean
duration of drug exposure was 46.5 days [standard devia-
tion (SD), 40.1 days] and 39.1 days (SD, 9.2 days) for
budesonide foam and placebo groups, respectively. The
total number of person-years of exposure was 91.2 in the
budesonide foam group and 29.8 in the placebo group.
In the current analysis, AEs were reported by 41.4 and
36.3 % of patients treated with budesonide foam and pla-
cebo, respectively (Table 2). Most AEs were mild or
moderate in intensity and occurred in a similar percentage
of patients in both groups, 93.3 and 96.0 % of patients
receiving budesonide foam or placebo, respectively. The
most common AEs (reported by C2 % of patients) in the
budesonide foam group were decreased blood cortisol
concentrations, headache, abdominal pain, and nausea.
Adverse events considered to be at least possibly related to
study drug occurred in 15.6 and 5.8 % of patients in the
budesonide foam and placebo groups, respectively.
The most common AEs (C5 patients) considered related
to treatment with budesonide foam were decreased blood
cortisol concentrations (6.1 %), adrenal insufficiency
(1.8 %), headache (1.0 %), abdominal pain (0.8 %), and
nausea (0.7 %). The incidence of glucocorticoid (noncor-
tisol)-related AEs of interest was low and not different
between budesonide foam and placebo. Adverse events
leading to study discontinuation were observed in 7.9 and
4.3 % of patients in the budesonide foam and placebo
groups, respectively. Serious AEs occurred in 8 (1.1 %)
and 3 (1.1 %) patients in the budesonide foam and placebo
groups, respectively; no deaths were reported during the
studies.
Mean morning cortisol concentrations remained within
normal limits in both treatment groups for the duration of
treatment, with the majority of patients in each group
Fig. 1 Patient disposition. The safety population for the budesonide
foam group (n = 719) included the budesonide foam groups in the
two placebo-controlled trials (n = 268) and two active-controlled
trials (n = 387), and the placebo-crossover group (n = 64) in the
open-label extension study. The safety population for the placebo
group (n = 278) included patients from two placebo-controlled trials
Dig Dis Sci (2015) 60:3408–3417 3411
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maintaining total cortisol concentrations above the lower
limit of normal ([138 nmol/L; 83.0 vs 93.1 % for budes-
onide foam and placebo groups, respectively; Fig. 2).
Although there was a slight decrease in mean morning
cortisol concentrations at weeks 1 and 2 during twice-daily
dosing in the budesonide foam group, the concentrations
were similar to baseline values by week 4. Further, the
majority of patients receiving budesonide foam or placebo
also maintained normal responses to ACTH challenge at
week 6 (86.1 vs 96.2 %, respectively; Table 3).
Pharmacokinetics
Overall, 1296 observations were available from a total of
145 patients and healthy volunteers in the PK population:
12 patients with mild-to-moderate UC from a phase I,
single-dose study, 18 healthy volunteers from a phase I
multiple-dose study, and 115 patients with mild-to-mod-
erate UP or UPS from two placebo-controlled phase III
trials. Overall, the PK population was 58.6 % male and
87.6 % white, with a mean age of 42.3 years.
Plasma concentrations of budesonide were below the
limit of quantitation (0.03 ng/mL) in 33 % of samples from
patients in the two placebo-controlled phase III trials. Mean
plasma budesonide concentrations in samples from patients
with concentrations above the limit of quantitation were
similar to those of samples from healthy volunteers in the
phase I multiple-dose study.
The estimated mean Cmax and mean AUC in the overall
PK population were 0.57 ng/mL and 4.31 ng h/mL,
respectively (Table 4). There were no substantial differ-
ences between patients with UC and healthy volunteers for
the PK parameters estimated. However, in the 115 patients
with UC, there was a statistically significant effect of UC
symptom severity on the elimination rate constant.
ACTH challenge test results at week 6 were compared
with estimates of plasma budesonide Cmax and AUC values
in combined data from BUCF3001 and BUCF3002. In this
Table 1 Demographics and
baseline characteristics (safety
population)
Characteristic Budesonide foam (n = 719) Placebo (n = 278)
Age (year), mean (SD) 43.4 (13.3) 41.6 (13.2)
Sex [n (%)]
Male 342 (47.6) 115 (41.4)
Female 377 (52.4) 163 (58.6)
Race [n (%)]
White 672 (93.5) 257 (92.4)
Black 33 (4.6) 13 (4.7)
Other 14 (1.9) 8 (2.9)
Body mass index (kg/m2), mean (SD) 25.7 (4.9)a 26.0 (5.1)
Duration of disease (year), mean (SD) 5.9 (7.3) 4.4 (6.0)
Extent of disease [n (%)]
Proctitisb 241 (33.5) 81 (29.1)
Proctosigmoiditisc 475 (66.1) 196 (70.5)
Missing 3 (0.4) 1 (0.4)
Severity of disease [n (%)]d
MMDAI score\ 4 4 (0.6) 0
Mild 192 (26.7) 34 (12.2)
Moderate 505 (70.2) 244 (87.8)
Severe 14 (1.9) 0
Missing 4 (0.6) 0
Baseline use of 5-ASA [n (%)] 228 (31.7) 154 (55.4)
5-ASA 5-aminosalicylic acid, CAI clinical disease activity index, DAI disease activity index, MMDAI
Modified Mayo Disease Activity Index
a n = 715
b Proctitis was defined as disease limited to the rectum (up to *15 cm from the anal verge)
c Proctosigmoiditis was defined as disease limited to the rectum and sigmoid colon (up to *40 cm from
the anal verge)
d Mild (MMDAI score 4–6); moderate (MMDAI score 7–10), and severe (MMDAI score 11–12) in
BUCF3001 and BUCF3002. Assessment of disease severity in study BUF-6/UCA by DAI and in study
BUF-9/UCA by CAI and DAI [17, 18]
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comparison, a negative correlation between ACTH chal-
lenge sensitivity, measured as the increase in serum cortisol
level in response to ACTH challenge, and plasma budes-
onide Cmax or AUC would be evidence of a biologically
plausible association between budesonide plasma concen-
trations and adrenal suppression. However, no negative
correlation between sensitivity to ACTH challenge and
budesonide plasma Cmax or AUC values was observed.
Table 2 Summary of adverse
events (safety population)
Adverse event [n (%)] Budesonide foam (n = 719) Placebo (n = 278)
Any AE 298 (41.4) 101 (36.3)
Drug-related AE 112 (15.6) 16 (5.8)
AE leading to discontinuation 57 (7.9) 12 (4.3)
Serious AEa 8 (1.1) 3 (1.1)
Most common AEsb
Decreased blood cortisol concentration 66 (9.2) 6 (2.2)
Headache 45 (6.3) 7 (2.5)
Abdominal pain 26 (3.6) 4 (1.4)
Nausea 18 (2.5) 2 (0.7)
Ulcerative proctitis 0 6 (2.2)
Glucocorticoid-related AEs
Acne 4 (0.6) 0
Agitation 1 (0.1) 0
Depression 4 (0.6) 1 (0.4)
Insomnia 3 (0.4) 1 (0.4)
Sleep disorder 1 (0.1) 0
Weight increase 2 (0.3) 1 (0.4)
AE adverse event, SAE serious adverse event, UC ulcerative colitis
a SAEs reported in budesonide foam group were: UC in two patients (severe in one patient and moderate in
one patient), severe abdominal pain, severe acute exanthematous pustulosis (only drug-related SAE
observed), severe arterial thrombosis limb, moderate diarrhea, moderate hypersensitivity, and mild unstable
angina in one patient each; in the placebo group: severe anemia, ectopic pregnancy of moderate severity,
and moderate UC in one patient each
b C2 % of patients in any group
Fig. 2 Mean morning cortisol
concentrations up to 8 weeks
for budesonide foam group and
6 weeks for placebo group. Data
are from the randomized-
controlled trials (placebo- and
active-controlled trials). Error
bars indicate standard
deviations. Morning cortisol
concentration results recorded
as a threshold value rather than
exact value were not imputed as
data for the figure
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Discussion
In this integrated analysis of safety from five phase III trials,
budesonide foam administered rectally for up to 8 weeks
was shown, overall, to be safe for patients with mild-to-
moderate UP or UPS, as treatment with budesonide foam
was associated with a low incidence of AEs. Pooling of
safety data for[700 patients exposed to budesonide foam
provided a robust assessment of the overall safety and
allowed for a better review of potentially uncommon AEs in
a larger patient population than was possible to assess from
each individual study alone. These data represent a com-
prehensive report regarding the safety of budesonide foam
for the treatment of patients with UP or UPS. Budesonide
foam has previously been shown to be efficacious for the
induction of remission in this patient population [17, 18, 23].
The incidence and severity of AEs and severe AEs
reported in this analysis were generally similar between
budesonide foam and placebo groups [18]. No clinically
significant adrenal suppression with budesonide foam
therapy was detected, confirming results from previous
studies with rectal budesonide preparations that showed
serum cortisol concentrations within normal range [24, 25].
These data are consistent with results observed with short-
term administration of oral budesonide preparations [26–
30]. This is likely because budesonide undergoes extensive
(*90 %) hepatic first-pass metabolism, forming metabo-
lites with little or no activity [31–33]. The incidence of
glucocorticoid (noncortisol)-related AEs, such as sleep
changes, acne, and weight gain, were rare and were similar
between budesonide foam and placebo groups; however,
assessment of potential glucocorticoid effects was not
prespecified in all study protocols. Serum cortisol con-
centrations had the greatest decrease during weeks 1 and 2,
compared with weeks 4 and 6; this effect was likely driven
by twice-daily dosing in weeks 1 and 2 in studies
BUCF3001 and BUCF3002, followed by subsequent daily
dosing for the last 4 weeks of these studies.
The population-based PK analysis demonstrated low
systemic exposure of budesonide foam. Budesonide foam
has a local-to-systemic exposure ratio of [40,000 to 1,
consistent with its local site of action in the distal colon.
Increases in budesonide systemic exposure (Cmax and
AUC) did not correlate with diminished response to ACTH
challenge. The majority of patients treated with budesonide
foam or placebo had normal HPA function with the ACTH
challenge test at week 6, findings driven by the BUCF3001
and BUCF3002 studies. These results suggest that exposure
to rectally administered budesonide at the doses studied for
up to 6–8 weeks does not have clinically relevant effects
on the HPA axis.
Table 3 Total cortisol
concentrations and normal
response to ACTH challenge
(randomized safety population)
Parameter, n/Na (%) Budesonide foam (n = 655)b Placebo (n = 278)b
Total cortisol[5 lg/dL (138 nmol/L)c
Baseline 622/638 (97.5) 275/278 (98.9)
Week 1 224/263 (85.2) 264/269 (98.1)
Week 2 315/366 (86.1) 263/266 (98.9)
Week 4 539/565 (95.4) 243/249 (97.6)
Week 6 211/224 (94.2) 234/241 (97.1)
Week 8 65/69 (94.2) –
Normal response to ACTH challenged,e
Baseline 261/266 (98.1) 275/278 (98.9)
Week 6 186/216 (86.1) 226/235 (96.2)
ACTH adrenocorticotropic hormone
a Denominator N is the number of patients with a value at each given week during the study
b Only patients in the four randomized studies were included
c Lower limit of normal
d The normal response to ACTH challenge, defined by protocol as a cortisol concentration of[ 18 lg/dL
(500 nmol/L) at 30 min following ACTH challenge
e Data based on patients in BUCF3001 and BUCF3002 studies
Table 4 Noncompartmental parameter estimates
Parameter, mean (CV) Pharmacokinetic population
(N = 145)
Clearance/F (L/h) 464 (640)
Volume of distribution/F (L) 2700 (274)
Absorption lag time (h) 0.149
AUC (ng h/mL) 4.31 (64)
Cmax (ng/mL) 0.573 (37)
AUC area under the curve, Cmax maximum plasma concentration, CV
coefficient of variation, F absolute bioavailability
3414 Dig Dis Sci (2015) 60:3408–3417
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A potential study limitation is that this analysis included
data from studies with minor differences in disease severity,
inclusion and exclusion criteria, and study duration. Also,
whether concomitant use of 5-ASAs at baseline was per-
mitted differed between the studies included in this analysis.
In the overall study population, a greater percentage of
patients receiving placebo used 5-ASAs at baseline; how-
ever, two studies did not permit concomitant use of 5-ASAs
at baseline. When these two studies were excluded from
analysis, the majority of patients receiving budesonide foam
used 5-ASAs at baseline. It is unclear whether baseline use
of 5-ASAs influenced the safety profile of budesonide foam.
However, a subgroup analysis (BUCF3001 and BUCF3002
studies) evaluating the potential impact of oral 5-ASA use
on the efficacy and safety of budesonide foam supports that
baseline oral 5-ASA use does not impact the tolerability and
safety profile of budesonide foam [34].
Results of this integrated analysis demonstrated a short
absorption lag time and a rapid absorption rate. A positive
finding from this analysis was the lack of a relationship
between presence of UP and UPS and PK parameters;
however, the severity of disease symptoms was predictive
of the elimination rate constant, with more severe symp-
toms predictive of decreased elimination. Comparisons of
PK parameters between rectally administered budesonide
foam and oral formulations of budesonide are limited by
the lack of pharmacokinetic data from oral formulations
available in patients with UP or UPS [35].
The findings of this comprehensive safety analysis,
together with published efficacy results, offer healthcare
providers and patients an additional rectally administered
therapeutic option for the induction of remission of UP and
UPS. Budesonide foam has a low incidence of clinically
relevant effects on the HPA axis as shown using ACTH
challenge and has a favorable safety profile, most likely
related to its minimal systemic exposure. While 5-ASA
treatment remains first-line therapy for the induction of
remission in patients with mild-to-moderate UP or UPS [2,
7, 9, 10], budesonide foam may be an efficacious and
better-tolerated alternative to systemic corticosteroids for
the treatment of mild-to-moderate UP or UPS. Indeed,
orally administered budesonide MMX has been shown to
have a favorable safety profile, with demonstrated efficacy
for the induction of remission of mild-to-moderate UC [27,
28]. Availability of both oral and rectal formulations makes
it possible for budesonide therapy to be integrated in the
current treatment algorithm: as an option after 5-ASAs and
before treatment with systemic corticosteroids [36]. In
conclusion, rectally administered budesonide foam had a
low incidence of AEs in this integrated safety analysis and
did not appear to adversely affect the HPA axis when used
to treat patients with mild-to-moderate distal UC.
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